ImmunityBio completed the merger with NantKwest for $2.85bn.

ImmunityBio, a privately-held immunotherapy company, completed the merger with NantKwest, a clinical-stage, natural killer cell-based therapeutics company, for $2.85bn. “With the integration of ImmunityBio’s pipeline, cutting-edge R&D capabilities, talented employees and clinical expertise, we expect to accelerate the delivery of new treatments for patients with unmet needs. Together we can unlock the combined potential of our assets, and look forward to building on our continued success as one company," Rich Adcock, NantKwest Chief Executive Officer. On February 25, 2021, Institutional Shareholder Services, Glass Lewis and Egan-Jones Proxy Services have recommended NantKwest stockholders vote “FOR” the pending merger with ImmunityBio.